Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Sep 18, 2026
TickeronGET DAILY SIGNALS
ProShares UltraPro Short Russell2000 (SRTY) Climbs +17.6% Amid Small-Cap Weakness

ProShares UltraPro Short Russell2000 (SRTY) Climbs +17.6% Amid Small-Cap Weakness

Key Takeaways

  • SRTY rose roughly +17.6% over the past 30 days, moving from around $21.19 to $24.91.
  • The advance stems from a notable decline in small-cap stocks, as SRTY targets -3x the daily return of the Russell 2000 Index.
  • Over the trailing quarter, SRTY gained approximately +9.6%.
  • The main driver has been a selloff in small caps fueled by higher Treasury yields, a hawkish Federal Reserve, and fresh inflation worries linked to energy prices.
  • Because SRTY resets daily and employs leverage, its results can differ substantially from a straightforward -3x multiple of the index over longer periods.

Understanding SRTY and Its Exposure

ProShares UltraPro Short Russell2000 (SRTY) is an inverse leveraged ETF that aims for daily results, before fees and expenses, equal to three times the inverse (-3x) of the Russell 2000 Index’s daily performance. In effect, the fund is built to gain when small-cap equities decline and lose when they rise.

The Russell 2000 Index covers about 2,000 of the smallest U.S. public companies, with an average market cap near $1.9 billion. Rather than holding stocks directly, SRTY gains its exposure mainly through derivatives like total return swaps and futures, supported by cash collateral, Treasury bills, and money market instruments. Its net expense ratio stands at about 0.95%, and the fund oversees roughly $75 million in assets.

This setup is worth noting when reviewing results. The fund’s -3x target resets each day, so returns compound over time and can stray noticeably from a simple -3x of the index’s overall move. Volatility in the Russell 2000 can therefore magnify or reduce SRTY’s performance beyond what a quick look at the index might imply. I also checked this using Tickeron’s AI Screener to see how the ETF stacks up against peers in the leveraged and inverse space.

Recent Price Moves: 30 Days and the Quarter

In the last 30 days, SRTY advanced from roughly $21.19 to $24.91, for a gain of about +17.6%. That corresponds to a decline of around 5.9% in the Russell 2000 over the same stretch, before daily compounding effects are factored in.

Over the quarter, the fund moved from about $22.72 to $24.91, or approximately +9.6%. The recent rise has followed a clear trend rather than staying range-bound, with the strongest gains coming during the August pullback and again in September as small-cap selling picked up. As a leveraged product, SRTY has shown higher daily volatility, with single-day swings often exceeding several percentage points.

Factors Behind the 30-Day Advance

SRTY’s recent performance tracks directly with weakness in U.S. small-cap equities. The Russell 2000 fell below its 50-day moving average in late August and kept sliding into September, marking what would be the index’s first quarterly decline since early 2025.

Several macro elements contributed to the drop. The 10-year Treasury yield rose toward its highest levels since October 2023, increasing borrowing costs for smaller firms that often carry more floating-rate debt and face near-term refinancing. The Federal Reserve added pressure with a rate hike and a hawkish tone focused on returning inflation to its 2% target. Rising energy prices, with Brent crude near $108 per barrel amid Middle East supply issues, heightened inflation concerns and further reduced appetite for risk in rate-sensitive small caps.

As the earlier small-cap rotation unwound, capital moved back toward larger, more defensive parts of the market. Since SRTY provides inverse exposure to this segment, the same pressures that hurt small caps supported the fund’s gains.

Quarterly Performance Drivers

The three-month picture shows a reversal. For much of the first half of the year, small-cap equities outperformed large caps on a broadening-market story tied to solid earnings growth. That edge faded as interest rates moved higher, energy costs increased, and financial conditions tightened.

Over the quarter, the Russell 2000 gave back earlier gains as leadership shifted back toward large-cap technology and semiconductor names. Institutional flows followed, pressuring small-cap products and aiding inverse exposure. For SRTY, this translated into a roughly +9.6% quarterly gain, even though daily-reset mechanics limited full -3x capture of the index’s decline.

Outlook for SRTY: Key Items to Monitor

The elements most likely to influence SRTY in the months ahead are the same ones behind its recent move. Interest-rate expectations remain central: any sign that the Federal Reserve will maintain its restrictive stance or that inflation stays elevated could keep yields higher and weigh further on small caps, supporting inverse exposure. On the other hand, signs of cooling inflation or a move toward easier policy would likely ease pressure on the Russell 2000 and work against the fund.

Energy prices and geopolitical developments in the Middle East also deserve attention, given their effect on inflation expectations and risk appetite. Small-cap earnings cycles, refinancing conditions, and the staying power of any rotation back into riskier areas will matter as well. Investors should keep in mind SRTY’s structure: as a daily -3x inverse fund, it suits short-term tactical use, and its compounding can produce results that differ sharply from a simple inverse position over longer periods.

Tracking Leveraged ETFs with AI Tools

When following products like SRTY, spotting the drivers behind small-cap and market moves matters. I’ve found Tickeron’s AI Screener helpful for scanning thousands of securities with technical indicators, fundamentals, volatility measures, price patterns, industry filters, and AI signals. It lets me set custom criteria and surface trending instruments or shifting leadership without manual effort, giving a structured way to review broader market dynamics alongside my own analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SRTY

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


SRTY's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for SRTY moved out of overbought territory on October 15, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In 24 of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for SRTY turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In 39 of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SRTY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 65 cases where SRTY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on SRTY as a result. In 87 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.

SRTY moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where SRTY advanced for three days, in 249 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

SRTY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 165 of 181 cases where SRTY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Industry description

The investment seeks daily investment results that correspond to three times the inverse (-3x) of the daily performance of the Russell 2000® Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a measure of small-cap U.S. stock market performance. Under normal circumstances, the fund will obtain inverse leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Trading

Category
Trading--Inverse Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
Analysts expect Q1 2026 revenue of $1.54 billion, reflecting approximately 74% year-over-year growth. Consensus earnings per share (EPS) forecast stands at $0.28, up over 115% from the prior year.
Analysts expect Q1 2026 revenue of $3.00 billion, up 8% from $2.77 billion in the year-ago quarter. Consensus earnings per share (EPS) estimate stands at $4.31, reflecting steady profitability from the cystic fibrosis (CF) portfolio.